Global News

Biota Pharmaceuticals to acquire Anaconda Pharma

Friday, February 27, 2015 02:29 PM

Biota Pharmaceuticals, based in Alpharetta, Ga., has agreed to acquire Anaconda Pharma, a privately held biotech company based in Paris.

More... »


JSR, CMIC and INCJ of Japan to acquire KBI Biopharma

Friday, February 27, 2015 02:27 PM

JSR, along with Tokyo-based CMIC and Innovation Network Corporation of Japan (INCJ), have agreed to acquire KBI Biopharma, a biopharmaceutical contract development and manufacturing organization with facilities in Durham and Research Triangle Park, N.C. and Boulder, Colo. Following completion of the acquisition, JSR will own the majority interest in KBI within the acquiring group.

More... »


Roche, BioMed X collaborate to develop nanomaterial-based biosensors

Thursday, February 26, 2015 03:30 PM

Roche and BioMed X, a collaboration model at the interface between academia and industry based in Heidelberg, Germany, have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene.

More... »

Huntingdon Life Sciences, Harlan Laboratories to rebrand

Thursday, February 26, 2015 03:21 PM

Huntingdon Life Sciences (HLS) and Harlan Laboratories will formally merge under one brand to reflect a new integrated management structure and broader product and service offerings of the combined organizations.

More... »

Stuart Horowitz appointed to ACRP editorial advisory board

Thursday, February 26, 2015 01:09 PM

WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services and software to support clinical research, has announced that Stuart Horowitz, Ph.D., M.B.A., its president of institutions and institutional services, has been appointed to the Association of Clinical Research Professionals' (ACRP's) editorial advisory board for a two-year term.

More... »

Quintiles named to Fortune magazine's 2015 list of World’s Most Admired Companies

Thursday, February 26, 2015 01:05 PM

Quintiles, a biopharmaceutical services company, has been named to Fortune magazine’s World’s Most Admired Companies list for 2015.

More... »

Palatin launches web site in support of phase III program for female sexual dysfunction

Thursday, February 26, 2015 12:15 PM

Palatin Technologies, a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, has launched a clinical trial web site (https://www.reconnectstudy.com) in support of its phase III reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).

More... »

BIO launches 2015 Everyday Superhero Contest

Thursday, February 26, 2015 11:00 AM

The Biotechnology Industry Organization (BIO) has announced a new contest aimed at recognizing biotech superheroes in the patient, industry and academic communities. Nominations will be accepted until March 5 for each of three categories: Patient/Patient Group, Pharma/Biotech and University/Research Institutions. Winners will be chosen by popular vote by March 31, and announced on site at the 2015 BIO International Convention, June 15-18 in Philadelphia, Pa.

More... »

Omeros's phase II OMS721 trial completes dosing, extended access for compassionate use

Thursday, February 26, 2015 10:45 AM

Omeros has completed dosing of the low-dose cohort of patients in its ongoing phase II clinical trial evaluating the efficacy and safety of OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, in treating thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.

More... »

Sosei acquires Heptares Therapeutics for up to $400M

Wednesday, February 25, 2015 11:36 AM

Sosei Group, a Japanese biopharmaceutical company with operations in Japan and the U.K., has acquired Heptares Therapeutics, a clinical-stage, private U.K.-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors (GPCRs).

More... »

`

CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs